About the 2022 Award



The Prix Galien USA Awards recognize excellence in biopharmaceutical research & development that have significantly improved the human condition. The Prix Galien is internationally renowned for recognizing the development of innovative medicines and medical technologies. Judged by a prestigious committee of scientists and clinicians, the Prix Galien is the ultimate acknowledgement among industry leaders and luminaries.

 

Eligibility:

To be eligible, products must have received marketing aproval in the USA by December 31 of the year preceding the award, but not more than 5 years earlier than December 31 of that year, unless the award is for a new and innovative indication, which must have been added within the previous 5 years.

The pharmaceutical, biotechnology, diagnostics and medical device products considered for the Prix Galien USA Award must be fully FDA approved (provisional approvals are not sufficient).

Awards:

Annual Award Categories (one to three awards per category)

Entries:

Each entry includes:
- Application and processing fees per drug, valid for 3 years (2022-2023-2024)
- Presentation of all entries in the 2022 Program Book
- Presentation of all finalists during the Awards Ceremony (video clip or digital presentation, 30 second maximum)
- A full page advertisement in the Awards Ceremony program
- Nominee certificate on behalf of the Prix Galien Committee
- Industry press publicity for all entries prior to the announcement of the winners
- Industry and general press publicity for the finalists before, during, and after the Awards Ceremony
- Online presentation of each entry on the Prix Galien USA website prior to the ceremony
- Video clip of finalists online on the Prix Galien USA website for one month following the ceremony
- Online presentation of winners until 2023 Prix Galien USA Awards Ceremony.

Submission process: